Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06388187 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06388187: Active Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
NCT06388187 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 300 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06388187, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.
Primary Outcome
Measured in percentage (%).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
- DRUG Cagrilintide
Study Locations (20)
Other
- Hospices Civils de Lyon-Hopital Lyon Sud-1 - Pierre-Bénite
- Hospices Civils de Lyon-Hopital Lyon Sud - Pierre-Bénite
- Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec - Saint-Herblain
- Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil - Toulouse
- InnoDiab Forschung GmbH - Essen
- Wendisch - Dahl Hamburg - DZHW - Hamburg
- AmBeNet GmbH - Leipzig
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose - Münster
- Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann - Witten
- The Health Centre - Bradford-on-Avon
California
- Aurora FDRC Inc. - Costa Mesa
Florida
- Clinical Trial Res Assoc,Inc - Plantation
Indiana
- Midwest Inst For Clin Res - Indianapolis
North Carolina
- Accellacare - Wilmington
Texas
- Velocity Clinical Res-Dallas - Dallas
Virginia
- Washington Cntr Weight Mgmt - Arlington
Washington
- Capital Clin Res Ctr,LLC - Olympia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2026-04-21 |
| Phase | Phase 3 |
What the registry record for NCT06388187 still lists
NCT06388187 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06388187 names 20 study sites across 11 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06388187 about?
NCT06388187 is a clinical study titled "A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight". This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy m...
What is the current status of trial NCT06388187?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2024-06-24. Estimated completion is 2026-04-21.
What conditions does trial NCT06388187 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06388187?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), Cagrilintide (DRUG).
Who is sponsoring clinical trial NCT06388187?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06388187 being conducted?
This trial has 20 study locations across California, Florida, Indiana, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06388187's enrollment target sits among peer trials
300 217th of 1053 higher than 825 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI